118 related articles for article (PubMed ID: 37074069)
21. Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post-PD-1 Immunotherapy.
Nielsen M; Presti M; Sztupinszki Z; Jensen AWP; Draghi A; Chamberlain CA; Schina A; Yde CW; Wojcik J; Szallasi Z; Crowther MD; Svane IM; Donia M
Cancer Immunol Res; 2022 Oct; 10(10):1254-1262. PubMed ID: 35969233
[TBL] [Abstract][Full Text] [Related]
22. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
23. An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN; Huang X; Vredevoogd DW; de Bruijn B; Traets JJH; Ibáñez-Molero S; Schieven SM; van Vliet A; Krijgsman O; Kuilman T; Pozniak J; Loayza-Puch F; Terry AM; Müller J; Logtenberg MEW; de Bruijn M; Levy P; Körner PR; Goding CR; Schumacher TN; Marine JC; Agami R; Peeper DS
Cell Rep Med; 2023 Feb; 4(2):100941. PubMed ID: 36812891
[TBL] [Abstract][Full Text] [Related]
24. Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients.
Pirozyan MR; McGuire HM; Emran AA; Tseng HY; Tiffen JC; Lee JH; Carlino MS; Menzies AM; Long GV; Scolyer RA; Fazekas de St Groth B; Hersey P
Front Immunol; 2020; 11():372. PubMed ID: 32210968
[TBL] [Abstract][Full Text] [Related]
25. Silencing of the interferon-inducible gene Ifi204/p204 induces resistance to interferon-γ-mediated cell growth arrest of tumor cells.
Yamaguchi H; Hiroi M; Ohmori Y
Cytokine; 2019 Jun; 118():80-92. PubMed ID: 30017387
[TBL] [Abstract][Full Text] [Related]
26. Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma.
Trujillo JA; Luke JJ; Zha Y; Segal JP; Ritterhouse LL; Spranger S; Matijevich K; Gajewski TF
J Immunother Cancer; 2019 Nov; 7(1):295. PubMed ID: 31703593
[TBL] [Abstract][Full Text] [Related]
27. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
28. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
29. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients.
Aspord C; Leccia MT; Salameire D; Laurin D; Chaperot L; Charles J; Plumas J
J Invest Dermatol; 2012 Oct; 132(10):2395-2406. PubMed ID: 22696054
[TBL] [Abstract][Full Text] [Related]
30. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
Ogasawara M; Rosenberg SA
Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
[TBL] [Abstract][Full Text] [Related]
31. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial.
Exley MA; Friedlander P; Alatrakchi N; Vriend L; Yue S; Sasada T; Zeng W; Mizukami Y; Clark J; Nemer D; LeClair K; Canning C; Daley H; Dranoff G; Giobbie-Hurder A; Hodi FS; Ritz J; Balk SP
Clin Cancer Res; 2017 Jul; 23(14):3510-3519. PubMed ID: 28193627
[No Abstract] [Full Text] [Related]
32. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
33. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
[TBL] [Abstract][Full Text] [Related]
34. Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma.
Ligtenberg MA; Pico de Coaña Y; Shmushkovich T; Yoshimoto Y; Truxova I; Yang Y; Betancur-Boissel M; Eliseev AV; Wolfson AD; Kiessling R
Mol Ther; 2018 Jun; 26(6):1482-1493. PubMed ID: 29735366
[TBL] [Abstract][Full Text] [Related]
35. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
[TBL] [Abstract][Full Text] [Related]
36. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.
Tsai WB; Aiba I; Lee SY; Feun L; Savaraj N; Kuo MT
Mol Cancer Ther; 2009 Dec; 8(12):3223-33. PubMed ID: 19934275
[TBL] [Abstract][Full Text] [Related]
37. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
38. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L
Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506
[TBL] [Abstract][Full Text] [Related]
39. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.
Huang SM; Wang A; Greco R; Li Z; Barberis C; Tabart M; Patel V; Schio L; Hurley R; Chen B; Cheng H; Lengauer C; Pollard J; Watters J; Garcia-Echeverria C; Wiederschain D; Adrian F; Zhang J
Oncotarget; 2014 May; 5(10):3362-74. PubMed ID: 24830942
[TBL] [Abstract][Full Text] [Related]
40. Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Zou J; Xia H; Zhang C; Xu H; Tang Q; Zhu G; Li J; Bi F
Cancer Sci; 2021 Jul; 112(7):2664-2678. PubMed ID: 33934451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
